Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension: ACCOMPLISH
Information source: Novartis
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Benazepril/amlodipine (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Novartis Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Chair, Affiliation: Novartis
Summary
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to
evaluate the effectiveness of the combination on reducing heart disease and death in a high
risk hypertensive population.
Clinical Details
Official title: A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack,stroke, hospitalization for chest pain or heart failure, or procedure to open a blockage in an arterial blood vessel
Secondary outcome: Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack,stroke, or hospitalization for heart failure or or procedure to open a blockage in an arterial blood vessel Risk of developing diabetes Progression of kidney disease
Eligibility
Minimum age: 55 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- At least 55 years of age.
- Have elevated blood pressure and at least one other cardiovascular disease or diabetes
or evidence of damage to the kidneys, brain, blood vessels or heart as defined in the
protocol
Exclusion Criteria:
- Allergy to any of the drugs administered in this trial. Selected laboratory tests.
Other protocol-defined exclusion criteria may apply.
Locations and Contacts
Novartis Pharmaceuticals, E. Hanover, New Jersey 07936, United States
Additional Information
Starting date: October 2003
Last updated: March 20, 2008
|
